STAAR Surgical (NASDAQ:STAA) Major Shareholder Buys $553,925.40 in Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. bought 31,780 shares of STAAR Surgical stock in a transaction on Wednesday, April 2nd. The shares were purchased at an average cost of $17.43 per share, for a total transaction of $553,925.40. Following the completion of the purchase, the insider now directly owns 12,487,044 shares of the company’s stock, valued at $217,649,176.92. This trade represents a 0.26 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Monday, March 31st, Broadwood Partners, L.P. purchased 22,189 shares of STAAR Surgical stock. The shares were purchased at an average price of $17.46 per share, with a total value of $387,419.94.
• On Thursday, March 27th, Broadwood Partners, L.P. acquired 3,620 shares of STAAR Surgical stock. The stock was acquired at an average price of $17.48 per share, for a total transaction of $63,277.60.
• On Tuesday, March 25th, Broadwood Partners, L.P. bought 34,296 shares of STAAR Surgical stock. The stock was acquired at an average price of $17.44 per share, for a total transaction of $598,122.24.
• On Thursday, March 20th, Broadwood Partners, L.P. purchased 108,720 shares of STAAR Surgical stock. The shares were acquired at an average price of $17.96 per share, with a total value of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. acquired 93,124 shares of STAAR Surgical stock. The stock was bought at an average price of $17.54 per share, for a total transaction of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. bought 249,503 shares of STAAR Surgical stock. The shares were bought at an average cost of $16.64 per share, with a total value of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. purchased 259,316 shares of STAAR Surgical stock. The stock was bought at an average cost of $17.05 per share, for a total transaction of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. acquired 36,532 shares of STAAR Surgical stock. The shares were bought at an average cost of $15.49 per share, with a total value of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. bought 259,616 shares of STAAR Surgical stock. The stock was purchased at an average cost of $14.96 per share, for a total transaction of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. acquired 8,221 shares of STAAR Surgical stock. The stock was purchased at an average cost of $21.50 per share, with a total value of $176,751.50.

STAAR Surgical Trading Down 8.5 %

Shares of NASDAQ:STAA opened at $15.92 on Friday. STAAR Surgical has a 52 week low of $13.50 and a 52 week high of $52.68. The company’s 50 day moving average is $18.82 and its two-hundred day moving average is $24.71. The company has a market cap of $785.25 million, a PE ratio of -38.83 and a beta of 0.75.

Wall Street Analyst Weigh In

A number of brokerages recently commented on STAA. Piper Sandler lowered their target price on STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating for the company in a report on Wednesday, February 12th. Stifel Nicolaus lowered their price objective on shares of STAAR Surgical from $38.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, February 12th. Jefferies Financial Group downgraded shares of STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th. Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a research report on Thursday, February 27th. Finally, Canaccord Genuity Group cut their price objective on STAAR Surgical from $28.00 to $17.00 and set a “hold” rating on the stock in a research report on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, STAAR Surgical currently has an average rating of “Hold” and an average price target of $25.29.

Hedge Funds Weigh In On STAAR Surgical

Several large investors have recently bought and sold shares of STAA. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of STAAR Surgical by 13.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 110,506 shares of the medical instruments supplier’s stock worth $2,684,000 after acquiring an additional 13,075 shares in the last quarter. Voloridge Investment Management LLC boosted its holdings in STAAR Surgical by 9.4% in the fourth quarter. Voloridge Investment Management LLC now owns 296,256 shares of the medical instruments supplier’s stock valued at $7,196,000 after purchasing an additional 25,350 shares in the last quarter. Squarepoint Ops LLC increased its stake in STAAR Surgical by 81.3% in the fourth quarter. Squarepoint Ops LLC now owns 117,074 shares of the medical instruments supplier’s stock valued at $2,844,000 after purchasing an additional 52,488 shares during the last quarter. Sherbrooke Park Advisers LLC purchased a new position in STAAR Surgical in the fourth quarter valued at approximately $502,000. Finally, Raiffeisen Bank International AG acquired a new stake in STAAR Surgical during the fourth quarter worth approximately $1,926,000. Hedge funds and other institutional investors own 96.70% of the company’s stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.